The GLG Healthcare Practice provides access to a global network of more than 55,000 experts from across the entire healthcare industry including physicians, researchers, scientists, and healthcare industry executives.
The Healthcare Practice provides insight into issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors.
Leading Experts include Council Members from GLG Member Programs. The Gerson Lehrman Group® (GLG) LeaderSM Program is our premium Member ProgramSM. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.
President, Managing Partner
2K Healthcare Solutions
Kevin Kearns, MD, is a board certified internist with a diverse background in academic medicine, clinical practice, health system medical management and managed care. Dr. Kearns has been Managing Partner for 2K Healthcare Solutions since February 2009....
MEDICAL TECHNOLOGY ASSOCIATES, INC
Henry Krause is Managing Partner and Vice President of Medical Technology Associates, a medical devices research and consulting firm involved in setting up channels and distribution strategies in Asian, North American and European markets for medical...
Pathology Lab of Georgia
John Cochran, MD, is the Founder and Chief Executive Officer of Chestatee Pathology Associates in Atlanta, GA, since 2001. Dr. Cochran is Medical Director of several metro-Atlanta CLIA-licensed, accredited laboratories and founded the first independent...
Chief Executive Officer
Vasilios Voudouris is Chief Executive Officer of Vereniki Solutions, a consultancy supporting the biotech/pharma industry. He also was an Executive Director at a leading US based CMO (Ampac Fine Chemicals) until Feb 2010 and was a Department Head at Nektar...
Founder and CEO
Rick Jung is the CEO of HealthFx, a provider of strategy consulting and ACO development services for hospitals, physician enterprises and RCM firms. He is also Chairman of the Board of Clinicient in Portland, OR, which provides integrated EHR and RCM...
|Study Group Name||No. Members|
There are no upcoming GLG Live Meetings
245 U.S.-based neurologists share their opinion of Tysabri for the treatment of multiple sclerosis.
How will Revlimid's use change with this new data? How will Carfilzomib fit into a crowded market?
Reactions from ten top medical oncologists, powered by the GLG Healthcare CouncilsSM, regarding data presented by Amgen and Bayer at the 34th European Society of Medical Oncology (ESMO) Congress in Berlin the week of September 21, 2009.